Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Oxycodone versus sufentanil for early recovery after minimally invasive esophagectomy
ChiCTR-IPR-17012493Phase 4Recruiting
- Sponsor
- Southern District of Anhui Provincial Hospital
- Start
- Sep 2017
- Modality
- Small Molecules, Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label trial of oxycodone and sufentanil in esophageal cancer (2 arms), sponsored by Southern District of Anhui Provincial Hospital. Primary endpoint: Cognitive function recovery. Started Sep 2017; status: recruiting.
02
Drugs
oxycodonesufentanil
03
Conditions
esophageal cancer
Beyond the preview
Go deeper on ChiCTR-IPR-17012493.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR-IPR-17012493.